Within the pharmaceutical industry, the mass spectrometer was long considered a
useful and challenging analytical tool largely limited to the specialist user.
The steady movement from specialist use to general use gained considerable speed
in the 1990s, particularly due to the development of practical, sensitive liquid
chromatography–mass spectrometry (LC–MS) interfaces and advances in the
microelectronics. The rapid proliferation of quadrupole ion trap, linear ion trap,
orbitrap, quadrupole mass filter, time-of-flight, and other types of mass spectrometers
has impacted the industry from the earliest stages of disease determination through
the final stages of clinical testing. This book, based on an American Society for
Mass Spectrometry (ASMS) session, which I was fortunate enough to chair, will
examine several of the ways in which mass spectrometry continues to have a profound
influence on the direction and speed of drug discovery and development, especially in
the area of drug metabolism (DM) and pharmacokinetics (PK).
0 comments:
Post a Comment